JERSEY CITY, NJ - May 5, 2010 - QUMAS, the leading provider of Compliance Solutions to highly regulated companies, today announced that MannKind Corporation has selected the QUMAS Biotechnology Package (based on the industry leading eDMS QUMAS DocCompliance) to improve document control and to reduce approval lifecycles of documents in a compliant environment. With this Package, MannKind is gaining access to a world class document management solution, packaged to ensure low acquisition and implementation costs while harnessing the strong functionality of DocCompliance.
MannKind Corporation chose QUMAS because it demonstrated the deepest understanding of MannKind's requirements, robust functional capabilities, and also brings the most experience in executing projects of this nature and scope. The experience of QUMAS staff and the configurability of the solution mean that MannKind will be able to deploy the Biotech Package very quickly, ensuring ease of adoption and fast track training. The scalable nature of the solution guarantees that it will meet the organizational needs as MannKind continues to grow. Future plans include deploying DocCompliance across the enterprise to include Quality, Legal, Marketing, Human Resources, and Finance.
"We needed to retire our legacy document management system and were in the market for not just a next generation, flexible system but also for a simple and elegant architecture from a company that had done this many times over and could lead us through this project," said Mark Sander, Vice President of Information Technology at MannKind Corporation. "We found QUMAS' compliance solutions to be very mature and on a strong technical platform and our conversations with QUMAS customers convinced us of QUMAS' ability to make our project a success."
"We are very pleased to add MannKind Corporation to our customer community," said Sefton Cohen, Vice President of Global Sales at QUMAS. "Our goal is to ensure that all growing biotechs not only have access to a leading eDMS which is currently in use in over 250 facilities globally but to ensure the industry can leverage the QUMAS compliance expertise, as configured in the system, to ensure a compliant organization from the outset, making biotechs more viable in a regulatory context and more attractive to investors and partners."
QUMAS is the leader in Enterprise Regulatory Compliance Solutions with more than 250 global customer deployments and over 15 years of experience in highly regulated industries. For more information, please visit www.qumas.com.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA(TM) and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted an NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response to this NDA. Currently, AFREZZA remains under regulatory review. Other products in its pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at www.mannkindcorp.com, to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.